Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults

Vaccine

Volumn 30, Issue 41, 2012, Pages 5973-5977

  Potsch, D V ^a   Camacho, L A B ^b   Tuboi, S ^c   Villar, L M ^b   Miguel, J C ^b   Ginuino C ^b   Silva, E F ^b   Mendonca R M M ^a   Moreira, R B ^a   Barroso, P F ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

Author keywords

Hepatitis B vaccination; HIV infection; Immune response

Indexed keywords

RECOMBINANT HEPATITIS B VACCINE;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROLOGY; TREATMENT RESPONSE; VACCINATION; VIRUS LOAD;

ADULT; ANTIBODY FORMATION; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; MALE; VACCINATION; VACCINES, SYNTHETIC; VIRAL LOAD;

EID: 84865346881     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.07.028     Document Type: Article

References (36)

1. Thio C.L., Seaberg E.C., Skolasky R., Phair J., Visscher B., Munoz A., et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002, 360(December (9349)):1921-1926.
2. Konopnicki D., Mocroft A., de Wit S., Antunes F., Ledergerber B., Katlama C., et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS 2005, 19(24 (6)):593-601.
3. Bruguera M., Cremades M., Salinas R., Costa J., Grau M., Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. J Clin Gastroenterol 1992, 14(January (1)):27-30.
4. Keet I.P., van Doornum G., Safary A., Coutinho R.A. Insufficient response to hepatitis B vaccination in HIV-positive homosexual men. AIDS 1992, 6(May (5)):509-510.
5. Tedaldi E.M., Baker R.K., Moorman A.C., Wood K.C., Fuhrer J., McCabe R.E., et al. Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin Infect Dis 2004, 38(May (10)):1478-1484.
6. Overton E.T., Sungkanuparph S., Powderly W.G., Seyfried W., Groger R.K., Aberg J.A. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005, 41(October (7)):1045-1048.
7. Mast E.E., Weinbaum C.M., Fiore A.E., Alter M.J., Bell B.P., Finelli L., et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep 2006, 55(December (RR-16)):1-33.
8. Kim H.N., Harrington R.D., Van Rompaey S.E., Kitahata M.M. Independent clinical predictors of impaired response to hepatitis B vaccination in HIV-infected persons. Int J STD AIDS 2008, 19(September (9)):600-604.
9. Fonseca M.O., Pang L.W., de Paula Cavalheiro N., Barone A.A., Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine 2005, 23(April (22)):2902-2908.
10. Cornejo-Juarez P., Volkow-Fernandez P., Escobedo-Lopez K., Vilar-Compte D., Ruiz-Palacios G., Soto-Ramirez L.E. Randomized controlled trial of Hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses. AIDS Res Ther 2006, 3:9.
11. Pasricha N., Datta U., Chawla Y., Singh S., Arora S.K., Sud A., et al. Immune responses in patients with HIV infection after vaccination with recombinant Hepatitis B virus vaccine. BMC Infect Dis 2006, 6:65.
12. Veiga A.P., Casseb J., Duarte A.J. Humoral response to hepatitis B vaccination and its relationship with T CD45 RA+ (naive) and CD45 RO+ (memory) subsets in HIV-1-infected subjects. Vaccine 2006, 24(November (49-50)):7124-7128.
13. Recommendations for preventing transmission of infections among chronic hemodialysis patients MMWR Recomm Rep 2001, 50(April (RR-5)):1-43.
14. Potsch D.V., Oliveira M.L., Ginuino C., Miguel J.C., Oliveira S.A., Silva E.F., et al. High rates of serological response to a modified hepatitis B vaccination schedule in HIV-infected adults subjects. Vaccine 2010, 28(February (6)):1447-1450.
15. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995, 854:1-452.
16. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years - United States. MMWR Recomm Rep 2008, 57(December (RR-10)):1-8.
17. Hadler S.C., Francis D.P., Maynard J.E., Thompson S.E., Judson F.N., Echenberg D.F., et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med 1986, 315(July (4)):209-214.
18. Bock H.L., Kruppenbacher J., Sanger R., Hobel W., Clemens R., Jilg W. Immunogenicity of a recombinant hepatitis B vaccine in adults. Arch Intern Med 1996, 156(October (19)):2226-2231.
19. Hofmann F., Kralj N. Criteria for successful hepatitis B vaccination in adults: results of a case study. Infection 2009, 37(June (3)):266-269.
20. Reed G.F., Meade B.D., Steinhoff M.C. The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 1995, 96(September (3 Pt 2)):600-603.
21. Cruciani M., Mengoli C., Serpelloni G., Lanza A., Gomma M., Nardi S., et al. Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patients. Vaccine 2009, 27(January (1)):17-22.
22. Launay O., van der Vliet D., Rosenberg A.R., Michel M.L., Piroth L., Rey D., et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA 2011, 305(April (14)):1432-1440.
23. Jilg W., Schmidt M., Deinhardt F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis 1989, 160(November (5)):766-769.
24. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Recomm Rep 1991, 40(November (RR-13)):1-25.
25. de Vries-Sluijs T.E., Hansen B.E., van Doornum G.J., Springeling T., Evertsz N.M., de Man R.A., et al. A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients. J Infect Dis 2008, 197(January (2)):292-294.
26. Stevens C.E., Alter H.J., Taylor P.E., Zang E.A., Harley E.J., Szmuness W. Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 1984, 311(August (8)):496-501.
27. Lao-araya M., Puthanakit T., Aurpibul L., Sirisanthana T., Sirisanthana V. Antibody response to hepatitis B re-vaccination in HIV-infected children with immune recovery on highly active antiretroviral therapy. Vaccine 2007, 25(July (29)):5324-5329.
28. Valdez H., Smith K.Y., Landay A., Connick E., Kuritzkes D.R., Kessler H., et al. Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 Team. AIDS Clinical Trials Group. AIDS 2000, 14(January (1)):11-21.
29. Pontesilli O., Kerkhof-Garde S., Notermans D.W., Foudraine N.A., Roos M.T., Klein M.R., et al. Functional T cell reconstitution and human immunodeficiency virus-1-specific cell-mediated immunity during highly active antiretroviral therapy. J Infect Dis 1999, 180(July (1)):76-86.
30. Gesemann M., Scheiermann N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995, 13(April (5)):443-447.
31. Floreani A., Baldo V., Cristofoletti M., Renzulli G., Valeri A., Zanetti C., et al. Long-term persistence of anti-HBs after vaccination against HBV: an 18 year experience in health care workers. Vaccine 2004, 22(January (5-6)):607-610.
32. McMahon B.J., Bruden D.L., Petersen K.M., Bulkow L.R., Parkinson A.J., Nainan O., et al. Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 2005, 142(March (5)):333-341.
33. Biggar R.J., Goedert J.J., Hoofnagle J. Accelerated loss of antibody to hepatitis B surface antigen among immunodeficient homosexual men infected with HIV. N Engl J Med 1987, 316(March (10)):630-631.
34. Hadler S.C. Hepatitis B prevention and human immunodeficiency virus (HIV) infection. Ann Intern Med 1988, 109(July (2)):92-94.
35. Australian Technical Advisory Group on Immunization (ATAGI) The Australian immunization handbook 2008, Australian Government, Department of Health and Ageing, Canberra. 9th ed.
36. Ministerio da Saude do Brasil, Fundação Nacional de Saúde Recomendações para vacinação em pessoas infectadas pelo HIV 2002, Ministério da Saúde, Brasília, DF.